Hoth Therapeutics shares explode 34% on what could be a life-saving cancer drug
In a significant breakthrough, Hoth Therapeutics Inc., a biopharmaceutical company focused on novel cancer treatments, saw its stock skyrocket by 34% after releasing compelling data from early-stage preclinical testing on HT-KIT, a potential cancer treatment targeting mast cell-related cancers. This surge reflects investors’ growing confidence in HT-KIT’s capabilities, positioning Hoth Therapeutics at the forefront of […]